New combo therapy aims to ease swallowing in advanced esophageal cancer

NCT ID NCT06290505

Recruiting now Disease control Sponsor: Australasian Gastro-Intestinal Trials Group Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase II trial is testing whether adding a targeted radiation dose and the immunotherapy drug durvalumab to standard chemotherapy and radiation can help people with advanced esophageal cancer who have trouble swallowing. The study will enroll 54 adults whose cancer has spread to a few other spots or is too advanced for surgery. The main goal is to see if this approach can keep the cancer from growing and improve swallowing symptoms.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Durvalumab (Imfinzi) plus chemotherapy and radiation
What this could lead to: If successful, this could offer a new treatment option that helps people with advanced esophageal cancer swallow more easily and live longer without their cancer getting worse.
What could go wrong: This is a small, early-phase trial with only 54 people, so results may not apply to everyone. Adding immunotherapy and extra radiation can cause serious side effects, and the cancer may still progress.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESOPHAGEAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

esophageal cancer Esophageal Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ESOPHAGEAL CANCER

Contacts and locations

Locations

Auckland Hospital
RECRUITING

Grafton, Auckland, 1023, New Zealand
Border Medical Oncology
ACTIVE_NOT_RECRUITING

Albury, New South Wales, 2640, Australia
Calvary Mater Newcastle
RECRUITING

Newcastle, New South Wales, 2298, Australia
Canberra Hospital
RECRUITING

Garran, Australian Capital Territory, 2605, Australia
Flinders Medical Centre
RECRUITING

Bedford Park, South Australia, Australia
Peter MacCallum Cancer Centre
RECRUITING

Melbourne, Victoria, 3000, Australia
Royal Brisbane and Women's Hospital
RECRUITING

Herston, Queensland, 4029, Australia
Sir Charles Gairdner Hospital
RECRUITING

Nedlands, Western Australia, 6009, Australia
St Vincent's Hospital
RECRUITING

Fitzroy, Victoria, 3065, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.